Hou Fang,Chen Jidong,Xia Meng,et al.Polidocanol injection under ultrasonic guidance for pediatric extremity venous malformations[J].Journal of Clinical Pediatric Surgery,2019,18(08):629-634.[doi:10.3969/j.issn.1671-6353.2019.08.003]
超声引导下聚多卡醇注射治疗儿童四肢静脉畸形的疗效分析
- Title:
- Polidocanol injection under ultrasonic guidance for pediatric extremity venous malformations
- Keywords:
- Venous Malformations; Polidocanol; Injections; Therapy; Ultrasonic Guidance; Child
- 分类号:
- R732.2;R453
- 摘要:
- 目的 探讨超声引导下聚多卡醇注射治疗儿童四肢静脉畸形的治疗效果及并发症。方法 回顾性收集2013年1月至2018年5月于电子科技大学附属四川省人民医院儿童医学中心收治的53例仅行超声引导下聚多卡醇注射治疗的四肢静脉畸形患儿作为研究对象，比较不同病灶部位和形态的治疗效果，观察记录病变体积变化、症状改善及并发症等情况。结果 53例患儿接受治疗时平均年龄为（3.8±3.1）岁。静脉畸形病灶位于上肢31例，下肢22例；局灶性41例，散发性12例。共进行了96人次注射治疗，每个患儿平均接受（1.8±0.9）次注射治疗。治疗完成后，10例疗效为优，29例为良，11例为中，3例为差。从不同病灶部位来看，31例上肢组患儿经治疗后有22例（70.97%）治疗效果为优良，22例下肢组患儿治疗后有17例（77.27%）治疗效果为优良，差异无统计学意义（χ2=0.263，P=0.608）；从病灶形态来看，41例局灶组中治疗效果为优良的34例（82.93%），12例散发组中治疗效果为优良的5例（41.67%），差异有统计学意义（χ2=6.146，P=0.013）。治疗期间及术后出现心率下降3人次；血压降低2人次，局部疼痛31人次，红肿87人次，发热30人次，暂时性感觉麻木5人次。所有患儿平均随访时间为（9.4±6.5）个月，未见复发病例。结论 超声引导下经皮穿刺聚多卡醇注射治疗对于儿童四肢的表浅及中小型静脉畸形，是一种疗效较好、简便易行、经济安全、微创无辐射且并发症少的方法。
- Abstract:
- Objective To explore the therapeutic efficacies and complications of injecting polidocanol for extremity venous malformations (VM) in children.Methods Fifty-three children with extremity VM received injections of polidocanol under ultrasonic guidance between January 2013 and May 2018.For comparing the therapeutic efficacies of different locations or distributions of VMs,the changes of lesion size,symptoms and complications were recorded.Results The mean age was (3.8±3.1) years.The sites of VM were upper extremity (n=31) and lower extremity (n=22).The lesions were focal (n=41) and diffuse (n=12).They received a total of 96 treatment sessions.The mean session was 1.8±0.9 per patient.After treatments,the outcomes were excellent (n=10),good (n=29),fair (n=11) and poor (n=3).And 22(70.97%) upper extremity and 17 (77.27%) lower extremity VM children had excellent/good outcomes.There was no statistical difference (χ2=0.263,P=0.608); 34(82.93%) focal and 5(41.67%) diffuse VM children had excellent/good outcomes.There were statistical differences (χ2=6.146,P=0.013).During and after treatments,the session number was bradycardia (n=3),hypotension (n=2),local pain (n=31),local swelling (n=87),fever (n=30) and transient local numbness (n=5).During a mean follow-up period of (9.4±6.5) months,there was no recurrence.Conclusion Polidocanol injection under ultrasonic guidance is both safe and effective for superficial,small and medium-sized extremity VMs in children.
参考文献/References:
1 Hoff SR,Rastatter JC,Richter GT.Head and neck vascular lesions[J].Otolaryngol Clin North Am,2015,48(1):29-45.DOI:10.1016/j.otc.2014.09.004.
2 Nassiri N,Thomas J,Cirillo-Penn NC.Evaluation and management of peripheral venous and lymphatic malformations[J].J Vasc Surg Venous Lymphat Disord,2016,4(2):257-265.DOI:10.1016/j.jvsv.2015.09.001.
3 Richter GT,Braswell L.Management of venous malformations[J].Facial Plast Surg,2012,28(6):603-610.DOI:10.1055/s-0032-1329935.
4 Manoli T,Micheel M,Ernemann U,et al.Treatment algorithm and clinical outcome of venous malformations of the limbs[J].Dermatol Surg,2015,41(10):1164-1170.DOI:10.1097/DSS.0000000000000469.
5 Muliken JB,Burrows PE,Fishman SJ.Vascular Anomalies:Hemangoiomas and Malformations.2nd ed[M].New York:Oxford university Press,2013:562-594.
6 Garzon MC,Huang JT,Enjolras O,et al.Vascular malformations-Part Ⅱ:associated syndromes[J].J Am Acad Dermatol,2007,56(4):541-564.DOI:10.1016/j.jaad.2006.05.066.
7 Hassanein AH,Mulliken JB,Fishman SJ,et al.Venous malformation risk of progression during childhood and adolescence[J].Ann Plast Surg,2012,68(2):198-201.DOI:10.1097/SAP.0b013e31821453c8.
8 Lee BB.Commentary on’ultrasound-guided intralesional diode laser treatment of congenital extratruncular venous malformations:mid-term results’[J].Eur J Vasc Endovasc Surg,2014,47(5):565.DOI:10.1016/j.ejvs.2014.02.021.
9 Ali S,Weiss CR,Sinha A,et al.The treatment of venous malformations with percutaneous sclerotherapy at a single academic medical center[J].Phlebology,2016,31(9):603-609.DOI:10.1177/0268355516633380.
10 Aronniemi J,Castren E,Lappalainen K,et al.Sclerotherapy complications of peripheral venous malformations[J].Phlebology,2016,31(10):712-722.DOI:10.1177/0268355515613740.
11 Horbach SE,Lokhorst MM,Saeed P,et al.Sclerotherapy for low-flowvascular malformations of the head and neck:a systematic review of sclerosing agents[J].J Plast Reconstr Aesthet Surg,2016,69(3):295-304.DOI:10.1016/j.bjps.2015.10.045.
12 Horbach SE,Rigter IM,Smitt J,et al.Intralesional bleomycin injections for vascular malformations:a systematic review and meta-analysis[J].Plast Reconstr Surg,2016,137(1):244-256.DOI:10.1097/PRS.0000000000001924.
13 Richter GT,Suen JY.Head and Neck Vascular Anomalies:A Practical Case-Based Approach.1st ed[M].San Diego:Plural Publishing,2014:141-143.
14 Pascarella L,Bergan JJ,Yamada C,et al.Venous ansgiomata:treatment with sclerosant foam[J].Ann Vasc Surg,2005,19(4):457-464.DOI:10.1007/s10016-005-4656-z.
15 Kaji N,Kurita M,Ozaki M,et al.Experience of sclerotherapy and embolosclerotherapy using ethanolamine oleate for vascular malformations of the head and neck[J].Scand J Plast Reconstr Surg Hand Surg,2009,43(3):126-136.DOI:10.1080/02844310902840296.
16 Hou F,Dai Y,Suen JY,et al.A xenograft animal model of human arteriovenous malformations[J].Orphanet J Rare Dis,2013,8:199.DOI:10.1186/1750-1172-8-199.
17 Guex JJ.Indications for the sclerosing agent polidocanol (aetoxisclerol dexo,aethoxisklerol kreussler)[J].J Dermatol Surg Oncol 1993,19(10):959-961.
18 Marrocco-Trischitta MM,Guerrini P,Abeni D,et al.Reversible cardiac arrest after polidocanol sclerotherapy of peripheral venous malformation[J].Dermatol Surg,2002,28(2):153-155.
19 Feied CF,Jackson JJ,Bren TS,et al.Allergic reactions to polidocanol for vein sclerosis.Two case reports[J].J Dermatol Surg Oncol,1994,20(7):466-468.
20 Cabrera J,Cabrera J Jr,Garcia-Olmedo MA,et al.Treatment of venous malformations with sclerosant in microfoam form[J].Arch Dermatol,2003,139(11):1409-1416.
21 Jain R,Bandhu S,Sawhney S,et al.Sonographically guided percutaneous sclerosis using 1% polidocanol in the treatment of vascular malformations[J].J Clin Ultrasound,2002,30(7):416-423.DOI:10.1002/jcu.10091.
22 Legiehn GM,Heran MK.Venous malformations:Classification,development,diagnosis,and interventional radiologic management[J].Radiol Clin North Am,2008,46(3):545-597.DOI:10.1016/j.rcl.2008.02.008.
23 Redondo P.Vascular malformations(Ⅱ). Diagnosis,pathology and treatment[J]. Actas Dermosifiliogr,2007,98(4):219-235.
24 Trop I,Dubois J,Guibaud L,et al.Soft-tissue venous malformations in pediatric and young adult patients:diagnosis with Doppler US[J].Radiology,1999,212(3):841-845.DOI:10.1148/radiology.212.3.r99au11841.
25 Legiehn GM,Heran MK.Classification,diagnosis,and interventionalradiologic management of vascular malformations[J].Orthop Clin North Am,2006,37(3):435-474.
26 Dubois J,Soulez G,Oliva VL,et al.Soft-tissue venous malformations in adult patients:imaging and therapeutic issues[J].Radiographics,2001,21(6):1519-1531.
27 Goyal M,Causer PA,Armstrong D.Venous vascular malformations in pediatric patients:comparison of results of alcohol sclerotherapy with proposed MR imaging classification[J].Radiology,2002,223(3):639-644.
相似文献/References:
[1]王怀杰,谢崇,蔺卫龙,等.纤维脂肪血管病变13例的诊断与治疗[J].临床小儿外科杂志,2022,21(07):668.[doi:10.3760/cma.j.cn101785-202102022-014]
Wang Huaijie,Xie Chong,Lin Weilong,et al.Diagnosis and treatment of fibro-adipose vascular anomaly(FAVA)[J].Journal of Clinical Pediatric Surgery,2022,21(08):668.[doi:10.3760/cma.j.cn101785-202102022-014]
备注/Memo
收稿日期:2019-04-22。
基金项目:国家自然科学基金青年基金（编号：81300238）；四川省科技厅青年基金（编号：2016JQ0059）；四川省科技厅重点研发项目（编号：2017FZ0040）；四川省卫生和计划生育委员会科研基金（编号：16PJ449）；中央高校科研基金（编号：ZYGX2016J171）
通讯作者:刘文英,Email:wenyingl@126.com